Suppr超能文献

[通过输注体外激活的自体淋巴细胞对晚期癌症进行生物治疗]

[Biotherapy of advanced cancer by infusion of in vitro activated autolymphocytes].

作者信息

Du X, Zhang M, Zhao M

机构信息

Department of Microbiology and Immunology, Henan Medical University, Zhengzhou.

出版信息

Zhonghua Zhong Liu Za Zhi. 1995 Nov;17(6):464-6.

PMID:8698005
Abstract

Autolymphocyte biotherapy is an adoptive cellular therapy based upon the infusion of autologous lymphocytes that have been activated in vitro by anti-CD3 monoclonal antibody and depleted of suppressor T cells by cimetidine, indomethacin and low dose of gamma irradiation. The patients also receive oral cimetidine to block suppressor T cell activity in vivo. Sixty five patients received 217 autolymphocyte infusions and toxicity was minimal with transient fever and chill accompanying 18 infusions. The efficacy of treatment in patients received more than 3 infusions were evaluated. In 37 evaluable patients, the response rate (CR+PR) was 24% (9/37). As the side reactions are mild, the treatment can be done on an outpatient basis.

摘要

自体淋巴细胞生物疗法是一种过继性细胞疗法,基于输注经抗CD3单克隆抗体体外激活并通过西咪替丁、吲哚美辛和低剂量γ射线照射清除抑制性T细胞的自体淋巴细胞。患者还口服西咪替丁以阻断体内抑制性T细胞的活性。65例患者接受了217次自体淋巴细胞输注,毒性极小,18次输注伴有短暂发热和寒战。对接受3次以上输注的患者的治疗效果进行了评估。在37例可评估患者中,缓解率(CR+PR)为24%(9/37)。由于副作用轻微,该治疗可在门诊进行。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验